Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. - Mari,A.; Sallas,WM.; He,YL.; Watson,C.; Ligueros-Saylan,M.; Dunning,BE.; Deacon,CF.; Holst,JJ.; Foley,JE. (J Clin Endocrinol Metab, 2005)